Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239915 | PMC |
| http://dx.doi.org/10.1016/j.jaip.2022.06.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the role of adhesin proteins in controlling infections: a systematic review.
Infect Immun
January 2025
Laboratory of Bacteriology and Bioassays, Federal University of Pelotas, Pelotas, Brazil.
Combating multidrug-resistant is considered a priority by the World Health Organization. Virulence mechanisms, such as biofilm formation, multidrug resistance, and high adherence to both biotic and abiotic surfaces, underscore the urgency of exploring approaches to control this pathogen. The search for new antibiotic compounds and alternative strategies like immunotherapies and vaccination offers potential solutions to address this pressing health concern.
View Article and Find Full Text PDFSafety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus.
Vaccines (Basel)
December 2024
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a recently emerged tickborne virus in east Asia with over 18,000 confirmed cases. With a high case fatality ratio, SFTSV has been designated a high priority pathogen by the WHO and the NIAID. Despite this, there are currently no approved therapies or vaccines to treat or prevent SFTS.
View Article and Find Full Text PDFRespiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.
Vaccines (Basel)
November 2024
Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Respiratory syncytial virus (RSV) is a leading cause of respiratory infections, particularly affecting young infants, older adults, and individuals with comorbidities. : This document, developed as a consensus by an international group of experts affiliated with the World Association of Infectious Diseases and Immunological Disorders (WAidid), focuses on recent advancements in RSV prevention, highlighting the introduction of monoclonal antibodies (mAbs) and vaccines. : Historically, RSV treatment options were limited to supportive care and the monoclonal antibody palivizumab, which required multiple doses.
View Article and Find Full Text PDFCurrent Non-Viral-Based Strategies to Manufacture CAR-T Cells.
Int J Mol Sci
December 2024
Medizinische Klinik und Poliklinik II und Lehrstuhl für Zelluläre Immuntherapie, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.
The successful application of CAR-T cells in the treatment of hematologic malignancies has fundamentally changed cancer therapy. With increasing numbers of registered CAR-T cell clinical trials, efforts are being made to streamline and reduce the costs of CAR-T cell manufacturing while improving their safety. To date, all approved CAR-T cell products have relied on viral-based gene delivery and genomic integration methods.
View Article and Find Full Text PDFAdoptive Transfer of CX3CR1-Transduced Tregs Homing to the Forebrain in Lipopolysaccharide-Induced Neuroinflammation and 3xTg Alzheimer's Disease Models.
Int J Mol Sci
December 2024
Department of Physiology, College of Korean Medicine, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemoon-gu, Seoul 02447, Republic of Korea.
CX3CR1-transduced regulatory T cells (Tregs) have shown potential in reducing neuroinflammation by targeting microglial activation. Reactive microglia are implicated in neurological disorders, and CX3CR1-CX3CL1 signaling modulates microglial activity. The ability of CX3CR1-transduced Tregs to inhibit LPS-induced neuroinflammation was assessed in animal models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!